Published in Clin Pharmacol Ther on January 01, 2007
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics (2010) 1.57
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol (2008) 1.42
The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol (2011) 1.41
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics (2011) 1.24
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem (2012) 1.18
Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. Biochemistry (2008) 1.11
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol (2011) 0.98
Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res (2014) 0.97
Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci (2009) 0.95
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics (2012) 0.94
Taxane pathway. Pharmacogenet Genomics (2009) 0.94
Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br J Clin Pharmacol (2012) 0.91
Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat (2012) 0.90
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol (2012) 0.89
The genetics of castration-resistant prostate cancer: what can the germline tell us? Clin Cancer Res (2008) 0.84
Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression. Endocrinology (2014) 0.82
Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy. AAPS J (2015) 0.78
Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. J Proteome Res (2016) 0.77
The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro. Drug Metab Dispos (2013) 0.76
Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. Breast Care (Basel) (2008) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
COPD prevalence in a random population survey: a matter of definition. Eur Respir J (2007) 2.97
Risk of venous thromboembolism in users of hormone replacement therapy. Lancet (1996) 2.92
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
IMGT, the international ImMunoGeneTics database. Nucleic Acids Res (1997) 2.43
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br J Pharmacol (1980) 2.31
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res (1999) 2.02
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J (2009) 1.99
The stereochemistry of the hydrogen elimination in the biological conversion of cholest-7-en-3-beta-ol into cholesterol. Biochem J (1967) 1.98
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Axonal GABA-receptors in mammalian peripheral nerve trunks. Brain Res (1978) 1.97
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther (2013) 1.94
Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology (1997) 1.92
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Dimethylthetin can substitute for glycine betaine as an osmoprotectant molecule for Escherichia coli. J Bacteriol (1987) 1.91
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer (2012) 1.90
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol (2013) 1.77
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 1.76
Complete nucleotide sequence of the chloroplast genome from the green alga Chlorella vulgaris: the existence of genes possibly involved in chloroplast division. Proc Natl Acad Sci U S A (1997) 1.75
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg (2003) 1.59
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis (2003) 1.59
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Role of formulation vehicles in taxane pharmacology. Invest New Drugs (2001) 1.58
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res (2000) 1.57
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst (2000) 1.57
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene (2012) 1.54
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Recommendations for locus-specific databases and their curation. Hum Mutat (2008) 1.49
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst (1996) 1.49
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med (1999) 1.48
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol (1998) 1.46
Role of allo-SCT for CML in 2010. Bone Marrow Transplant (2010) 1.46
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc (1999) 1.46
Laser capture microscopy. Mol Pathol (2000) 1.43
Peripheral neurotoxicity induced by docetaxel. Neurology (1996) 1.42
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Reduction of polypharmacy by feedback to clinicians. J Gen Intern Med (1991) 1.41
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol (2001) 1.41
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res (1994) 1.39
Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol (2001) 1.38
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients. Int J Gynecol Cancer (2007) 1.38
Measles immunisation. Aust J Public Health (1992) 1.38